Latest "Therapure Biopharma" News Stories

22:11 EDT 19th March 2018 | BioPortfolio

Here are the most relevant search results for "Therapure Biopharma" found in our extensive news archives from over 250 global news sources.

More Information about Therapure Biopharma on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Therapure Biopharma for you to read. Along with our medical data and news we also list Therapure Biopharma Clinical Trials, which are updated daily. BioPortfolio also has a large database of Therapure Biopharma Companies for you to search.

Showing "Therapure Biopharma" News Articles 1–25 of 2,300+

Extremely Relevant

Therapure Biopharma Inc. Wins the Mississauga Board of Trade’s 2017 Business Awards of Excellence

Therapure Biopharma Inc. announces that it is the recipient of the Mississauga Board of Trade’s (MBOT’s) 2017 Business Awards of Excellence. Hundreds of members and honoured guests were on hand for this sold out event, held at the Mississauga Convention Centre on Thursday, November 16, 2017. In winning the MBOT award, Therapure demonstrated: ...


KBI Biopharma: How to stand out in the CMO space

KBI Biopharma is a CMO focused exclusively on biologics. Bernardo Estupinan-Gaisbauer, Vice President – Business Development at KBI Biopharma, discusses their strategy for partnering, and the challenges of staying competitive in the CMO sector.

BioPharma Ambition 2018: Live updates from an all-island event

In between NIBRT site tours and tax workshops in Dublin Castle, Biopharma-Reporter is covering BioPharma Ambition on the Emerald Isle.

BioPharma Dive's 3 predictions for 2018 and beyond

What trends will shape the biopharma industry in 2018? BioPharma Dive's editors took a stab at predicting how the year may unfold for AI, oncology and neuroscience.

ARRAY BIOPHARMA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Array Biopharma, Inc. To Contact The Firm

NEW YORK, NY / ACCESSWIRE / January 11, 2018 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Array Biopharma, Inc. ("Array Biopharma" or the "Company") (NASDAQ:...

Critical Survey: Galena Biopharma (GALE) vs. Its Peers

Galena Biopharma is one of 116 publicly-traded companies in the "Pharmaceuticals" industry, but how does it compare to its peers? We will compare Galena Biopharma to similar companies based on the strength of its analyst recommendations, dividends, profitability, risk, institutional ownership, earnings and valuation. 20.5% of Galena Biopharma shares are owned by institutional investors.

ACC CEO leaving to head new biopharma company

American College of Cardiology CEO Shalom “Shal” Jacobovitz is leav

#jobs #lifescience (Senior) Manager, Regulatory Operations – Biopharma

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: (Senior) Manager, Regulatory Operations – Biopharma .MA-Waltham, Direct-hire opportunity for a Manager or Associate Director of Regulatory Operations! This is a newly created role with a growing biotech … Continue reading → Cet article #jobs #lifescience (Sen...

New SAFE-BioPharma Standard Trust List Enables Validation of Digital Signatures in Both US and EU

A newly published SAFE-BioPharma Trust List vastly improves workflows involving sensitive and proprietary electronic documents exchanged between the US and the EU. When incorporated into the EU framework, the Trust List can allow European Relying Parties to validate digital signatures issued by SAFE-BioPharma certified providers in the same way they can va...

RedHill Biopharma Ltd.: RedHill Biopharma Prices Public Offering of its American Depositary Shares

TEL-AVIV, Israel and RALEIGH, N.C., 2017-11-08 15:15 CET (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmac...

IPO raises $66.2M for Cue BioPharma

An initial public offering brought in $66.2 million for Cue BioPharma.  -More- 

STAT Plus: The mood at #JPM18: Biopharma really, really loves the tax overhaul

Biopharma companies are positively giddy about the new tax law. Here's why.

Hemispherx Biopharma And UNMC Take On Pancreatic Cancer

NewsThe University of Nebraska Medical Center and Hemispherx Biopharma, Inc. are joining forces to take on pancreatic cancer, one of the most deadly forms of cancer.

Vitality Biopharma Completes Pivotal GMP Manufacturing Agreements for Cannabinoid Pharmaceuticals / R&D operations in California registered with DEA to enable production of new class of cannabinoid pharmaceuticals

LOS ANGELES, CA -- (Marketwired) -- 11/01/17 -- Vitality Biopharma, Inc. (OTCQB: VBIO) ("Vitality Biopharma," "Vitality," or the "Company") a corporation dedicated to the development of cannabinoi...

I-Mab Biopharma buys rights to HyLeukin

In a second significant in-licensing deal this month, Shanghai, China-based I-Mab Biopharma receives…

Theravance Biopharma and Mylan Submit NDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease

DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Nov. 13, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced the submission of a New Drug Application...

PDL BioPharma drops pursuit of Neos

PDL BioPharma today officially announced it will no longer pursue its proposed acquisition of US modified-release…

I-Mab Biopharma gets rights to myeloma drug for China in up to $120 million deal

MorphoSys has entered into an agreement with Shanghai-based I-Mab Biopharma granting the latter an exclusive…

STAT Plus: 7 ways biopharma would win — and lose — under the new tax bill

Biopharma can find plenty to celebrate — and a few things to despair — in the new Republican plan to rewrite the tax code.

Enteris BioPharma's Partner Doses First Patient With New Drug

NewsCara Therapeutics, partnering with Enteris BioPharma, has initiated the Phase One clinical trial of its oral Korsuva in patients with chronic liver disease. Enteris will continue to manufacture the oral tablet formulation through Phase Two.

Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease

DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Jan. 29, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced that the U.S. Food and Drug...

Cue Biopharma and Merck to develop biologics for autoimmune diseases

US-based company Cue Biopharma has entered a strategic research collaboration and licence agreement with Merck to focus on the development...Read More... The post Cue Biopharma and Merck to develop biologics for autoimmune diseases appeared first on Pharmaceutical Technology.

Sutro Biopharma: origins, platform technology and competitive advantage

In this interview, filmed at BioPharm in San Francisco, Dr Fintan Walton speaks with William J Newell, Chief Executive Officer at Sutro Biopharma, a biopharma drug development firm They discuss the company's: • origins and business model • collaborations • platform technology, how it works and its advantages over its competitors’ platforms • plans for the future

GT Biopharma ends dosing in Phase l trial of GTP-004

GT Biopharma has completed dosing patients in a Phase l trial of GTP-004 for the treatment of myasthenia gravis symptoms....Read More... The post GT Biopharma ends dosing in Phase l trial of GTP-004 appeared first on Drug Development Technology.

STAT Plus: From the C-Suite: Biopharma execs open up on what tests them as leaders

Each month, biopharma executives share insights about leadership and management — and tips for thriving in a roller-coaster industry.

Quick Search


News Quicklinks